[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.5808/GI.2019.17.3.e23

Identification of neoantigens derived from alternative splicing and RNA modification

Park, Jiyeon (Precision Medicine Research Center, College of Medicine, The Catholic University of Korea)
Chung, Yeun-Jun (Precision Medicine Research Center, College of Medicine, The Catholic University of Korea)

Publication Information

Abstract

The acquisition of somatic mutations is the most common event in cancer. Neoantigens expressed from genes with mutations acquired during carcinogenesis can be tumor-specific. Since the immune system recognizes tumor-specific peptides, they are potential targets for personalized neoantigen-based immunotherapy. However, the discovery of druggable neoantigens remains challenging, suggesting that a deeper understanding of the mechanism of neoantigen generation and better strategies to identify them will be required to realize the promise of neoantigen-based immunotherapy. Alternative splicing and RNA editing events are emerging mechanisms leading to neoantigen production. In this review, we outline recent work involving the large-scale screening of neoantigens produced by alternative splicing and RNA editing. We also describe strategies to predict and validate neoantigens from RNA sequencing data.

Keywords

alternative splicing; neoantigen; RNA editing;

Citations & Related Records

Reference

1	Kahles A, Ong CS, Zhong Y, Ratsch G. SplAdder: identification, quantification and testing of alternative splicing events from RNA-Seq data. Bioinformatics 2016;32:1840-1847. DOI
2	Smart AC, Margolis CA, Pimentel H, He MX, Miao D, Adeegbe D, et al. Intron retention is a source of neoepitopes in cancer. Nat Biotechnol 2018;36:1056-1058. DOI
3	Saletore Y, Meyer K, Korlach J, Vilfan ID, Jaffrey S, Mason CE. The birth of the Epitranscriptome: deciphering the function of RNA modifications. Genome Biol 2012;13:175. DOI
4	Nishikura K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol 2016;17:83-96. DOI
5	Hsiao YE, Bahn JH, Yang Y, Lin X, Tran S, Yang EW, et al. RNA editing in nascent RNA affects pre-mRNA splicing. Genome Res 2018;28:812-823. DOI
6	Laurencikiene J, Kallman AM, Fong N, Bentley DL, Ohman M. RNA editing and alternative splicing: the importance of co-transcriptional coordination. EMBO Rep 2006;7:303-307. DOI
7	Ramaswami G, Li JB. RADAR: a rigorously annotated database of A-to-I RNA editing. Nucleic Acids Res 2014;42:D109-D113. DOI
8	Picardi E, D'Erchia AM, Lo Giudice C, Pesole G. REDIportal: a comprehensive database of A-to-I RNA editing events in humans. Nucleic Acids Res 2017;45:D750-D757. DOI
9	Li X, Xiong X, Yi C. Epitranscriptome sequencing technologies: decoding RNA modifications. Nat Methods 2016;14:23-31. DOI
10	Gatsiou A, Vlachogiannis N, Lunella FF, Sachse M, Stellos K. Adenosine-to-inosine RNA editing in health and disease. Antioxid Redox Signal 2018;29:846-863. DOI
11	Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, et al. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med 2016;8:11. DOI
12	Tan MH, Li Q, Shanmugam R, Piskol R, Kohler J, Young AN, et al. Dynamic landscape and regulation of RNA editing in mammals. Nature 2017;550:249-254. DOI
13	Kim S, Kim HS, Kim E, Lee MG, Shin EC, Paik S, et al. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. Ann Oncol 2018;29:1030-1036. DOI
14	Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, et al. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat Commun 2018;9:3919. DOI
15	Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell 2018;34:211-224. DOI
16	Slansky JE, Spellman PT. Alternative splicing in tumors: a path to immunogenicity? N Engl J Med 2019;380:877-880. DOI
17	Lee CH, Yelensky R, Jooss K, Chan TA. Update on tumor neoantigens and their utility: why it is good to be different. Trends Immunol 2018;39:536-548. DOI
18	Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, et al. Systematic analysis of splice-site-creating mutations in cancer. Cell Rep 2018;23:270-281. DOI
19	Kozlovski I, Siegfried Z, Amar-Schwartz A, Karni R. The role of RNA alternative splicing in regulating cancer metabolism. Hum Genet 2017;136:1113-1127. DOI
20	Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene 2016;35:2413-2427. DOI
21	Shiraishi Y, Kataoka K, Chiba K, Okada A, Kogure Y, Tanaka H, et al. A comprehensive characterization of cis-acting splicing-associated variants in human cancer. Genome Res 2018;28:1111-1125. DOI
22	Park E, Pan Z, Zhang Z, Lin L, Xing Y. The expanding landscape of alternative splicing variation in human populations. Am J Hum Genet 2018;102:11-26. DOI
23	Tian J, Wang Z, Mei S, Yang N, Yang Y, Ke J, et al. CancerSplicingQTL: a database for genome-wide identification of splicing QTLs in human cancer. Nucleic Acids Res 2019;47:D909-D916. DOI
24	Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep 2018;23:282-296. DOI
25	Saha A, Kim Y, Gewirtz ADH, Jo B, Gao C, McDowell IC, et al. Co-expression networks reveal the tissue-specific regulation of transcription and splicing. Genome Res 2017;27:1843-1858. DOI
26	Vitting-Seerup K, Sandelin A. The landscape of isoform switches in human cancers. Mol Cancer Res 2017;15:1206-1220. DOI
27	Ben-Aroya S, Levanon EY. A-to-I RNA editing: an overlooked source of cancer mutations. Cancer Cell 2018;33:789-790. DOI
28	Poulos MG, Batra R, Charizanis K, Swanson MS. Developments in RNA splicing and disease. Cold Spring Harb Perspect Biol 2011;3:a000778. DOI
29	Braunschweig U, Barbosa-Morais NL, Pan Q, Nachman EN, Alipanahi B, Gonatopoulos-Pournatzis T, et al. Widespread intron retention in mammals functionally tunes transcriptomes. Genome Res 2014;24:1774-1786. DOI
30	Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E. The functional impact of alternative splicing in cancer. Cell Rep 2017;20:2215-2226. DOI
31	Liu Y, Gonzalez-Porta M, Santos S, Brazma A, Marioni JC, Aebersold R, et al. Impact of alternative splicing on the human proteome. Cell Rep 2017;20:1229-1241. DOI
32	Xu X, Wang Y, Liang H. The role of A-to-I RNA editing in cancer development. Curr Opin Genet Dev 2018;48:51-56. DOI
33	Yang X, Coulombe-Huntington J, Kang S, Sheynkman GM, Hao T, Richardson A, et al. Widespread expansion of protein interaction capabilities by alternative splicing. Cell 2016;164:805-817. DOI
34	Efremova M, Finotello F, Rieder D, Trajanoski Z. Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol 2017;8:1679. DOI
35	Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019;51:202-206. DOI
36	Carazo F, Romero JP, Rubio A. Upstream analysis of alternative splicing: a review of computational approaches to predict context-dependent splicing factors. Brief Bioinform 2018 Jan 29 [Epub]. https://doi.org/10.1093/bib/bby005.
37	Singh B, Eyras E. The role of alternative splicing in cancer. Transcription 2017;8:91-98. DOI
38	Peng X, Xu X, Wang Y, Hawke DH, Yu S, Han L, et al. A-to-I RNA editing contributes to proteomic diversity in cancer. Cancer Cell 2018;33:817-828. DOI
39	Roth SH, Danan-Gotthold M, Ben-Izhak M, Rechavi G, Cohen CJ, Louzoun Y, et al. Increased RNA editing may provide a source for autoantigens in systemic lupus erythematosus. Cell Rep 2018;23:50-57. DOI